BioAge to Host R&D Day Focused on NLRP3 Inhibition on May 8, 2026
Stocks in this Quantisnow insightHealth Care
Historical context for BIOA
Across the 18 sessions after earlier BIOA headlines, the stock closed higher 11 times and lower 7 times, with a median move of 5.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | BIOA | SPY |
|---|---|---|---|
| Apr 21, 2026 | BioAge Reports Positive Phase 1 Data for BGE-102, a Novel Oral NLRP3 Inhibitor, Demonstrating Potential Best-in-Class Reductions in hsCRP | +4.3% | -0.7% |
| Apr 14, 2026 | BioAge Labs to Present at 25th Annual Needham Virtual Healthcare Conference | +2.3% | +1.2% |
| Mar 27, 2026 | Needham initiated coverage on BioAge Labs with a new price target | -0.6% | -1.7% |
| Mar 24, 2026 | BioAge Labs Reports Full Year 2025 Financial Results and Provides Business Updates from the Fourth Quarter of 2025 | -13.5% | -0.3% |
| Mar 23, 2026 | New data on long-term, real-world treatment with lecanemab presented at the 2026 AD/PD™ congress | -3.5% | +1.1% |
| Feb 25, 2026 | Oppenheimer initiated coverage on BioAge Labs with a new price target | +2.7% | +0.8% |
Keep researching BIOA
Quantisnow market dataNASDAQ
BIOA
BioAge Labs Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2024
Get push alerts for BIOA
Full BIOA profile on Quantisnow Follow BIOA and get a push notification the moment its next story breaks.